

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

MASSFELDER et al.

Serial No.

10/520,085

Filed:

January 5, 2005

SEP 21 2005 W

Atty. Ref.:

3665-133

Group:

2829

Examiner:

Unknown

For:

USE OF PTHRP ANTAGONISTS FOR TREATING RENAL

**CELL CARCINOMA** 

Commissioner for Patents

P.O. Box 1450 Alexandria, VA 22313-1450 **September 21, 2005** 

Sir:

## INFORMATION DISCLOSURE STATEMENT

 $\boxtimes$ PTO-1449 Pursuant to 37 CFR 1.97(b) 1. [within 3 months of filing or prior to 1st Office Action on the merits] N/C 2.(a) Statement Pursuant to 37 CFR 1.97(c) [before Final Office Action or Allowance (requires Rule 97(e) Statement or Rule 17(p) fee)] N/C 2 .(b) Fee Payment Pursuant to 37 CFR 1.97(c) [before Final Office Action or Allowance (requires Rule 97(e) \$180.00 Statement or Rule 17(p) fee)] 3. Pursuant to 37 CFR 1.97(d) [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment] \$180.00

37 C.F.R. §§ 1.97 and 1.98:  $\boxtimes$ 4. A list of documents on Form PTO-1449 together with copies of each identified document and a translation or a concise explanation of each non-English language document (such as a Search Report) is enclosed herewith. This paper is submitted in accordance with:  $\boxtimes$ 5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]  $\Box$ 6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and a) The required Statement made in item 8 below; or П b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below. П 7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and П b) The required Statement is stated in item 8 below. 8. Statement under 37 CFR 1.97(e) a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37

The following are submitted in the above-identified application in compliance with

Disclosure Statement.

CFR §1.56(c) more than three months prior to the filing of this Information

9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted, NIXON & VANDERHYE P.C.

By: \_\_\_\_

Reg. No. 36,663

901 North Glebe Road, 11th Floor

Arlington, VA 22203-1808 Telephone: (703) 816-4000 Facsimile: (703) 816-4100 Sheet 1 of 1

INFORMATION DISCLOSURE ATTY, DOCKET NO.				SERIAL NO.				
			3665-133		0/520,085			
		APPLIC	ANT				-	
	several sheets if pecessary)	MASS	SFELDER et al.					
(Use s	several sheets if pecesary)	GROUP						
	/	Janua	ary 5, 2005	2829				
	SEP 21	~~~~	. PATENT DOCUMENTS					
*EXAMINER			NAME	CLASS	SUBCLASS	FILING	DATE	
INITIAL	*EXAMINER INITIAL DOCUMENT UMBER		A NAME		OLAGO GOBOLAGO		II ATTHORNALE	
				,		<u> </u>		
				<u> </u>		·		
		FORI	<u>EIGN PATENT DOCUMEN</u>	TS		TRANS	LATION	
	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO	
	EP 1 197 225 A1	04/2002	Europe					
						ļ	ļ	
						<b></b>		
						ļ	ļ	
	OTHER ROOM	ENTO (1	aludina Author Title Dete	Dominant = :	l case sate	<u> </u>	<u> </u>	
Т			cluding Author, Title, Date ad Biophysical Research Co				No	
	3, pp 1134-1138					OI. 107	, INO.	
	Savage et al, Journal of Endocrinology, 1993, Vol. 137, No. suppl., p P57							
	Hoare et al, Peptides, 2002, Vol. 23, No. 5, pp 989-998							
	Akino et al, Endocrinology, 2000, Vol. 141, No. 11, pp 4313-4316							
			· · · · · · · · · · · · · · · · · · ·				<del></del>	
*Examiner			Date Considered					
	if reference considered, whether of with next communication to applic		conformance with MPEP 609; Draw line through	gh citation if not in confo	rmance and not	considered	. Include	
					Form PTO-FB-	A820 (Also	PTO-1449	